Mar 2010 abstract: Incidence and management of (Avastin) bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

METHODS: We identified all patients who received bevacizumab off protocol from August 2004-August 2008. We examined their medical records for reports of confirmed GI perforation, associated clinicopathological factors, treatment, and outcomes. RESULTS: Six (4%) of 160 patients with ovarian carcinoma who had been treated with bevacizumab developed GI perforation.